Shipp (2002)

John Ramey edited this page Dec 29, 2012 · 1 revision


According to Shipp et al. (2002), approximately 30-40% of adult non-Hodgkin lymphomas are diffuse large B-cell lymphomas (DLBCLs). However, only a small proportion of DLBCL patients are cured with modern chemotherapeutic regimens. Several models have been proposed, such as the International Prognostic Index (IPI), to determine a patient's curability. These models rely on clinical covariates, such as age, to determine if the patient can be cured and are often ineffective. Shipp et al. (2002) have argued that more effective means are desired to determine a patient's curability. The authors measured 6,817 gene expression levels from 58 DLBCL patient samples with customized cDNA ('lymphochip') microarrays to investigate the curability of patients treated with cyclophosphamide, adriamycin, vincristine, and prednisone (CHOP)-based chemotherapy. Among the 58 DLBCL patient samples, 32 are from cured patients while 26 are from patients with fatal or refractory disease.

The above description is from Ramey and Young (2011).

Sample Size Number of Features Number of Classes Disease
58 6,817 2 Lymphoma

Data Source and Preprocessing



Link to Original Paper

BibTeX Record

author = {Shipp, Margaret A and Ross, Ken N and Tamayo, Pablo and Weng, Andrew P and Kutok, Jeffery L and Aguiar, Ricardo C T and Gaasenbeek, Michelle and Angelo, Michael and Reich, Michael and Pinkus, Geraldine S and Ray, Tane S and Koval, Margaret A and Last, Kim W and Norton, Andrew and Lister, T Andrew and Mesirov, Jill and Neuberg, Donna S and Lander, Eric S and Aster, Jon C and Golub, Todd R},
title = {{Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning.}},
journal = {Nature Medicine},
year = {2002},
volume = {8},
number = {1},
pages = {68--74},
month = jan